Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

Novel therapeutic approach to primary biliary cirrhosis patients: anti-eosinophil strategy

Miyaguchi, S.; Oda, M.; Saito, H.; Ishii, H.

Hepato-Gastroenterology 45(23): 1457-1461

1998

ISSN/ISBN: 0172-6390
PMID: 9840083
Document Number: 493304
BACKGROUND/AIMS: Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown cause. Morphologically, PBC is characterized by eosinophil infiltration into the portal tract in recent studies. Pranlukast, a new drug, is a leukotriene antagonist, which suppresses eosinophil infiltration in atopic dermatitis or asthma. METHODOLOGY: In this study, pranlukast monotherapy was used to treat 12 patients with a diagnosis of PBC, classified as stage I or II according to Scheuer's classification on the basis of liver biopsy findings. RESULTS: An improvement in alkaline phosphatase (ALP) was observed beginning one month after the start of pranlukast therapy in all 12 patients. Improvement in ALP and Y-GTP values was stastically observed at 1, 2, and 6 months after the start of treatment. IgG and IgM values improved in all 12 patients at 2 months and 6 months after the start of treatment. Absolute eosinophil counts improved at 6 months after the start of treatment. CONCLUSIONS: Given its efficacy and the absence of side effects, planlukast appears to be the medical treatment of choice for patients with early-stage PBC. But, a randomized, controlled, double-blind trial is urgently needed.

Document emailed within 1 workday
Secure & encrypted payments

Novel therapeutic approach to primary biliary cirrhosis patients: anti-eosinophil strategy

Abenavoli, L. 2009: Primary biliary cirrhosis: therapeutic options Recenti Progressi in Medicina 100(9): 417-423
Larsson, E.J.; Ganc, A.J.; Miszputen, S.J.; Reibscheid, S.; Vilela, M.P. 1973: Primary biliary cirrhosis: diagnostic and therapeutic aspects Revista Paulista de Medicina 82(3): 123-128
Geubel, A.P. 1979: Primary biliary cirrhosis. Recent etiopathogenic and therapeutic data Acta Gastro-Enterologica Belgica 42(9-10): 390-402
Miyachi, K.; Shibata, M.; Hasegawa, C.; Onozuka, Y.; Fritzler, M.J. 2005: Case of primary biliary cirrhosis patient with anti-p97/VCP antibodies presenting a mild clinical course Rinsho Byori. Japanese Journal of Clinical Pathology 53(1): 19-23
Caponi, A.; Lisotti, A.; Grenci, C.; Roda, E. 2008: Are therapeutic doses of ursodeoxycholic acid in the cure of primary biliary cirrhosis inadequate? Some clinical considerations Minerva Gastroenterologica E Dietologica 54(4): 331-334
Williams, C.N.; MacDonald, I.A.; Park-Dincsoy, H. 1979: Primary bile acid kinetics in patients with primary biliary cirrhosis and in normal subjects Clinical and Investigative Medicine. Medecine Clinique et Experimentale 2(1): 29-40
Brahm, J.; Chesta, J. 1993: Bacteriuria in patients with primary biliary cirrhosis Revista Medica de Chile 121(5): 499-502
Van Den Bogaert, E.; Francque, S.; Pelckmans, P.; Michielsen, P. 2003: The use of ursodeoxycholic acid in patients with primary biliary cirrhosis: sense or nonsense Acta Gastro-Enterologica Belgica 66(4): 283-287
Kurien, B.T.; Scofield, R.H. 1998: Multiple nuclear dot antinuclear antibody in patients without primary biliary cirrhosis Indian Journal of Biochemistry and Biophysics 35(1): 41-47
Parsons, H.G.; Thirsk, J.E.; Frohlich, J.; Dias, V.; Minuk, G.Y. 1989: Effect of cyclosporin A on serum lipids in primary biliary cirrhosis patients Clinical and Investigative Medicine 12(6): 386-391
Penner, E.; Muller, S.; Zimmermann, D.; Van Regenmortel, M.H. 1987: High prevalence of antibodies to histones among patients with primary biliary cirrhosis Clinical and Experimental Immunology 70(1): 47-52
Batts, K.P.; Jorgensen, R.A.; Dickson, E.R.; Lindor, K.D. 1996: Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis American Journal of Gastroenterology 91(11): 2314-2317
Sotaniemi, E.A.; Hynnynen, T.; Ahlqvist, J.; Ahokas, J.T.; Puoskari, U.; Pelkonen, I. 1978: Effects of medroxyprogesterone on the liver function and drug metabolism of patients with primary biliary cirrhosis and chronic active hepatitis Journal of Medicine 9(2): 117-128
Broomé, U.; Hauzenberger, D.; Klominek, J. 1996: Adhesion molecules in primary biliary cirrhosis and primary sclerosing cholangitis Hepato-Gastroenterology 43(11): 1109-1112
Salaspuro, M.P.; Laitinen, O.I.; Lehtola, J.; Makkonen, H.; Räsänen, J.A.; Sipponen, P. 1976: Immunological parameters, viral antibodies, and biochemical and histological findings in relatives of patients with chronic active hepatitis and primary biliary cirrhosis Scandinavian Journal of Gastroenterology 11(3): 313-320
Epstein, O.; Chapman, R.W.; Lake-Bakaar, G.; Foo, A.Y.; Rosalki, S.B.; Sherlock, S. 1982: The pancreas in primary biliary cirrhosis and primary sclerosing cholangitis Gastroenterology 83(6): 1177-1182
Kong, F.; Li, J-Xin.; Li, P.; Li, Y-Zhe.; Zhang, F-Chun.; Zhang, J. 2013: Association of TNFSF4 polymorphisms with susceptibility to primary Sjögren's syndrome and primary biliary cirrhosis in a Chinese Han population Clinical and Experimental Rheumatology 31(4): 546-551
Ter Borg, P.C.J.; Hagendorf, A.; van Buuren, H.R.; Koper, J.W.; Lamberts, S.W.J. 2004: A pilot study exploring the role of glucocorticoid receptor variants in primary biliary cirrhosis and primary sclerosing cholangitis Netherlands Journal of Medicine 62(9): 326-331
Vlahcevic, Z.R.; Yoshida, T.; Juttijudata, P.; Bell, C.C.; Swell, L. 1973: Bile acid metabolism in cirrhosis. 3. Biliary lipid secretion in patients with cirrhosis and its relevance to gallstone formation Gastroenterology 64(2): 298-303
Schoen, U.; Kasper, H. 1978: Primary biliary cirrhosis Die Medizinische Welt 29(14): 583-587